BioMarin Co-Pay Assistance Programs are for commercially insured patients only, and certain terms and conditions may apply. If you qualify, the Co-Pay Assistance Programs may reduce your out-of-pocket responsibility and you will be automatically enrolled each year, as long as you remain eligible.
Full Answer
How to report a problem with BioMarin?
What is the email address for patient advocacy?
What is BMN 270?
Is BMN 111 safe for children?
About this website
A holistic approach to care
We are committed to the communities we treat beyond the therapies we develop. From support services to grants and donations to arts programs and school scholarships, we believe in providing patients, their families and their advocates with the tools they need to live their best lives.
Grants & Donations
We provide a variety of opportunities to further support our patient communities.
Resources
For each disease state we seek to treat, there are a number of organizations and resources that provide great insight and support services.
How to report a problem with BioMarin?
If you are already participating in a BioMarin clinical trial and wish to report a problem with the study drug or side effect (s), please contact your study doctor as soon as possible , and please email us at [email protected] or [email protected].
What is the email address for patient advocacy?
If you are from an advocacy group and have questions regarding Patient Advocacy activities, please contact: [email protected]
What is BMN 270?
Learn about the BioMarin gene therapy clinical trial program for BMN 270, an investigational gene therapy for hemophilia A. Take a closer look at how clinical trials for hemophilia A are being designed and the current progress of BMN 270. This webinar recording also reviews the Complete Response Letter (CRL) from the FDA and what it means.
Is BMN 111 safe for children?
BMN 111 is being researched, it has not been approved for use or been determined to be safe or effective. This is a recording made from a live, educational webinar, hosted by The MAGIC Foundation and sponsored by BioMarin. The webinar is presented by Teresa Tucker, Co-Founder and Patient Advocate for The MAGIC Foundation, and Lynda Polgreen, MD, MS, of The Lundquist Institute at Harbor-UCLA Medical Center.
Grants
Grants provide funding for a variety of events, activities, and projects that benefit patients, the scientific or medical community, and/or public health in areas of legitimate interest to BioMarin.
Donations
Donations provide funding for benevolent purposes such as improvement of healthcare, patient care or advocacy, civic projects, disaster relief, access to healthcare, or programs for children.
Resources
For each disease state we seek to treat, there are a number of organizations and resources that provide great insight and support services.
Verification
Please provide your initials below to confirm that you have provided complete and accurate information in your application.
Disclosures
In order to receive benefits under a BioMarin Co-Pay Assistance Program, it is important that you provide accurate information. Your personal information is required for security purposes and is only used to confirm your eligibility for enrollment in the BioMarin Co-Pay Assistance Program and to administer the program.
Verification
Please provide your initials below to confirm that you have provided complete and accurate information in your application.
Disclosures
In order to receive benefits under a BioMarin Co-Pay Assistance Program, it is important that you provide complete and accurate information. Your personal information is required for security purposes and is only used to confirm your eligibility for enrollment in the BioMarin Co-Pay Assistance Program and to administer the program.
Verification
Please provide your initials below to confirm that you have provided complete and accurate information in your application.
Disclosures
In order to receive benefits under a BioMarin Co-Pay Assistance Program, it is important that you provide complete and accurate information. Your personal information is required for security purposes and is only used to confirm your eligibility for enrollment in the BioMarin Co-Pay Assistance Program and to administer the program.
Committed beyond the medicine
We support programs and activities that foster excellence in patient care and provide valuable scientific, medical, and educational information to the medical and scientific communities. We also support clinicians and the independent research they conduct to advance knowledge about rare diseases and/or BioMarin’s therapies and products.
Our Products
Each of our seven approved therapies reset the standard of care for the conditions they treat.
Our Pipeline
Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.
How long after giving a pynzq injection should you watch for signs of a reaction?
Your healthcare provider may recommend that an adult observer (or your caregiver) be with you when you give your PALYNZIQ injection and for at least 1 hour after your injection to watch you for signs and symptoms of a severe allergic reaction and, if needed, give you an injection of epinephrine and call for emergency medical help
What is the dosage of pallinzq?
PALYNZIQ ® (Pal-lin-zeek) (pegvaliase-pqpz) is a prescription medication used to lower blood levels of phenylalanine (Phe) in adults with PKU (phenylketonuria) who have uncontrolled blood Phe levels above 600 micromol/L (10 mg/dL) on their current treatment.
Can you change the protein in your diet during a pynzIQ?
Your healthcare provider may change the amount of protein and Phe you should have in your diet during treatment with PALYNZIQ, depending on the levels of Phe in your blood. Follow your healthcare provider’s instructions about the amount of protein and Phe you should have in your diet.
Can you take epinephrine with a palanziq?
Keep the auto -injectable epinephrine with you at all times during treatment with PALYNZIQ. Read the Patient Information that comes with the auto-injectable epinephrine that your healthcare provider prescribes for you for more information.
Can you give a palynzq?
Your healthcare provider will decide if you (or your caregiver) are able to give the PALYNZIQ injections, recognize the signs and symptoms of a severe allergic reaction, give an injection of epinephrine, and call for emergency help, if needed
How to report a problem with BioMarin?
If you are already participating in a BioMarin clinical trial and wish to report a problem with the study drug or side effect (s), please contact your study doctor as soon as possible , and please email us at [email protected] or [email protected].
What is the email address for patient advocacy?
If you are from an advocacy group and have questions regarding Patient Advocacy activities, please contact: [email protected]
What is BMN 270?
Learn about the BioMarin gene therapy clinical trial program for BMN 270, an investigational gene therapy for hemophilia A. Take a closer look at how clinical trials for hemophilia A are being designed and the current progress of BMN 270. This webinar recording also reviews the Complete Response Letter (CRL) from the FDA and what it means.
Is BMN 111 safe for children?
BMN 111 is being researched, it has not been approved for use or been determined to be safe or effective. This is a recording made from a live, educational webinar, hosted by The MAGIC Foundation and sponsored by BioMarin. The webinar is presented by Teresa Tucker, Co-Founder and Patient Advocate for The MAGIC Foundation, and Lynda Polgreen, MD, MS, of The Lundquist Institute at Harbor-UCLA Medical Center.
Investigational Medicines
Hemophilia Clinical Trial Information
- Learn about the BioMarin gene therapy clinical trial program for BMN 270, an investigational gene therapy for hemophilia A. Take a closer look at how clinical trials for hemophilia A are being designed and the current progress of BMN 270. This webinar recording also reviews the Complete Response Letter (CRL) from the FDA and what it means.
BioMarin in The Community
- We have partnered closely with numerous patient advocacy organizations and their members to listen to and understand communities, highlight clinical trial opportunities and develop educational materials to build awareness of rare diseases across the world. For a list of patient organizations and resources, please click here.
Collaborations
- Listen as our expert faculty discuss achondroplasia, the most common form of dwarfism, and share an overview of the clinical program for BMN 111, the investigational treatment BioMarin is studying in children with achondroplasia. BMN 111 is being researched, it has not been approved for use or been determined to be safe or effective. This is a recording made from a live, educatio…
Contact
- If you are from an advocacy group and have questions regarding Patient Advocacy activities, please contact: [email protected] If you are interested in participating in a BioMarin clinical trial and would like to contact someone to learn more, please send a message to [email protected]. If you are already participating in a BioMarin clinical t...